NZ505887A - Multi-binding compounds; useful as beta2-adrenergic receptor agonists - Google Patents
Multi-binding compounds; useful as beta2-adrenergic receptor agonistsInfo
- Publication number
- NZ505887A NZ505887A NZ505887A NZ50588799A NZ505887A NZ 505887 A NZ505887 A NZ 505887A NZ 505887 A NZ505887 A NZ 505887A NZ 50588799 A NZ50588799 A NZ 50588799A NZ 505887 A NZ505887 A NZ 505887A
- Authority
- NZ
- New Zealand
- Prior art keywords
- binding compounds
- adrenergic receptor
- attached
- ligands
- receptor agonists
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A â2-adrenergic receptor agonist compound of formula II and its salts, wherein: Ar1 and Ar3 are aryl, heteroaryl or heterocyclyl; Ar2 is (a) phenylene, wherein W and X are attached at the 1,2-, 1,3- or 1,4-position of the ring; (b) cyclohexylene optionally substituted with methyl, wherein W and X are attached at the 1,3- or 1,4-position of the cyclohexylene ring; and (c) piperazinylene, wherein W and X are attached at the 1,4-positions of the piperazinylene ring; Q is -NHCH2CH(OH)-; W is alkylene or substituted alkylene; and X is a covalent bond. â2-adrenergic receptor agonists are multi-binding compounds of formula II that bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as congestive heart failure, pulmonary hypertension, cerebral vasospasm following subarachnoid hemorrhage, essential hypertension, myocardial infarction, myocardial ischemia, unstable angina, restenosis, renal failure of ischemic origin, portal hypertension, cardiac hypertrophy, atherosclerosis, eclampsia, cerebrovascular disease, vascular disease, migraines, and auto-immune diseases, such as Morbus Wegener and Morbus Raynaud, to name a few. These multi-binding compounds (â2-adrenergic receptor agonists) comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes/functions thereof. Each of the ligands, which may be the same or different, is covalently attached to a linker or linkers which may be the same or different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation of the biological processes mediated by the endothelin receptor than that provided by the ligands in monomeric form. The specification also discloses pharmaceutical compositions comprising the multi-binding compounds, methods of inhibiting and treating the disorders mediated by endothelin receptors, and methods of preparing these multi-binding compounds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ505887A NZ505887A (en) | 1999-06-07 | 1999-06-07 | Multi-binding compounds; useful as beta2-adrenergic receptor agonists |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ505887A NZ505887A (en) | 1999-06-07 | 1999-06-07 | Multi-binding compounds; useful as beta2-adrenergic receptor agonists |
| PCT/US1999/011804 WO1999064035A1 (en) | 1998-06-08 | 1999-06-07 | β2-ADRENERGIC RECEPTOR AGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ505887A true NZ505887A (en) | 2003-01-31 |
Family
ID=19928010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ505887A NZ505887A (en) | 1999-06-07 | 1999-06-07 | Multi-binding compounds; useful as beta2-adrenergic receptor agonists |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ505887A (en) |
-
1999
- 1999-06-07 NZ NZ505887A patent/NZ505887A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999063936A3 (en) | Novel therapeutic agents that modulate endothelin receptors | |
| US7309787B2 (en) | Kinase inhibitors | |
| JP4772690B2 (en) | Tubulin inhibitor | |
| US6090809A (en) | 1-(4-arylpiperazin-1-yl)-ω-[n-(α..omega.-dicarboximido)]-alkanes useful as uro-selective α1 -adrenoceptor blockers | |
| US6541504B1 (en) | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | |
| HUP0301094A2 (en) | Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing this compounds and their use | |
| IS2313B (en) | 1,3-dihydro-2H-indol-2-one derivatives and their use as binders for V1b or V1b and V1a arginine urinary antagonists | |
| Jia et al. | Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents | |
| EA200500875A1 (en) | DERIVATIVES OF 3-AMINOPYRROLIDIN AS A MODULATOR OF CHEMOKINE RECEPTORS | |
| DE60023318D1 (en) | Heteropolycyl compounds and their use as antagonists of metabotropic glutamate receptors | |
| TW222642B (en) | ||
| Orjales et al. | New (2-Methoxyphenyl) piperazine Derivatives as 5-HT1A Receptor Ligands with Reduced. alpha. 1-Adrenergic Activity. Synthesis and Structure-Affinity Relationships | |
| BG106423A (en) | Isomeric fused pyrrolocarbazoles and isoindolones | |
| AU2001228212A1 (en) | Beta-turn peptidomimetic cyclic compounds | |
| KR950005311A (en) | Thienopyrimidine Derivatives, Methods for Making and Uses thereof | |
| WO2003038054A3 (en) | Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds | |
| Roose et al. | Iron‐Catalysed Carbene Transfer to Isocyanides as a Platform for Heterocycle Synthesis | |
| ATE500224T1 (en) | PRODUCTION PROCESS FOR CARBOXAMIDE-PYRIDINE DERIVATIVES AS INTERMEDIATE PRODUCTS IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | |
| Yamamoto et al. | Specific alkylation of human telomere repeat sequences by a tandem-hairpin motif of pyrrole–imidazole polyamides with indole-seco-CBI | |
| Njoroge et al. | Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity | |
| EA200101234A1 (en) | NEW AMINOTHYAZOL DERIVATIVES, THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| DE69923587D1 (en) | NON-PEPTIDIC ANTAGONISTS OF GLP-1 RECEPTOR AND METHODS OF USE | |
| KR880007477A (en) | Imidazole derivatives and preparation method thereof | |
| NZ505887A (en) | Multi-binding compounds; useful as beta2-adrenergic receptor agonists | |
| DE50114321D1 (en) | RECEPTOR OF EDB FIBRONECTINE DOMAIN (II) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |